Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis
Objective This study aimed to compare treatment patterns and healthcare costs for patients with psoriasis who initiate apremilast, tumor necrosis factor inhibitor, or interleukin inhibitor. Methods This retrospective cohort study used Optum Clinformatics® Data Mart to identify propensity score–match...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2023.2177095 |
| _version_ | 1797683468086280192 |
|---|---|
| author | Jashin J. Wu Ching An Wang Greeta Jobson David Davidson Samaneh Kalirai Julia Zhu Manasi Suryavanshi Mayank Mittal Vardhaman Patel Lauren Seigel |
| author_facet | Jashin J. Wu Ching An Wang Greeta Jobson David Davidson Samaneh Kalirai Julia Zhu Manasi Suryavanshi Mayank Mittal Vardhaman Patel Lauren Seigel |
| author_sort | Jashin J. Wu |
| collection | DOAJ |
| description | Objective This study aimed to compare treatment patterns and healthcare costs for patients with psoriasis who initiate apremilast, tumor necrosis factor inhibitor, or interleukin inhibitor. Methods This retrospective cohort study used Optum Clinformatics® Data Mart to identify propensity score–matched patients initiating apremilast, tumor necrosis factor inhibitors, or interleukin inhibitors, with 12-month baseline and 24-month follow-up data. Switch, discontinuation, persistence, healthcare resource utilization, and total healthcare costs were assessed. Results Twenty-four-month switch rates were highest for tumor necrosis factor inhibitors (32%), followed by apremilast (21%) then interleukin inhibitors (14%). Mean (SD) per-patient-per-month costs for switchers were lowest for apremilast ($4213 [$2304]), higher for tumor necrosis factor inhibitors ($5274 [$2280]), and highest for interleukin inhibitors ($5539 [$2296]; p < .001), primarily attributable to pharmacy costs: $3466 (apremilast), $4432 (tumor necrosis factor inhibitor), and $4721 (interleukin inhibitor). Limitations Psoriasis severity is absent from claims data; cost outcomes may be influenced by more severe psoriasis being more costly. Conclusion Switching psoriasis treatment is common and increases over time. Apremilast initiators had lower switch rates and costs compared with tumor necrosis factor inhibitors, despite lower effectiveness reported in previous studies, perhaps indicating patient preference for oral treatment. Additional oral options may be desirable for this population. |
| first_indexed | 2024-03-12T00:14:52Z |
| format | Article |
| id | doaj.art-5b6db17de9fb40db8013d1b1a84cc912 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:14:52Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-5b6db17de9fb40db8013d1b1a84cc9122023-09-15T14:28:53ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532023-12-0134110.1080/09546634.2023.21770952177095Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysisJashin J. Wu0Ching An Wang1Greeta Jobson2David Davidson3Samaneh Kalirai4Julia Zhu5Manasi Suryavanshi6Mayank Mittal7Vardhaman Patel8Lauren Seigel9Department of Dermatology, University of Miami Miller School of MedicineReal-World Analytics & Data Science (RADS), CORDS-CIF for Cardiovascular, Immunology and Fibrosis, Bristol Myers SquibbOffshore DeliveryImmunology and Fibrosis, Bristol Myers SquibbWorldwide HEOR – US Market, Immunology, Bristol Myers SquibbReal-World Analytics & Data Science (RADS), CORDS-CIF for Cardiovascular, Immunology and Fibrosis, Bristol Myers SquibbHEOR Markets Department, Bristol Myers SquibbOffshore DeliveryWorldwide HEOR – US Market, Immunology, Bristol Myers SquibbWorldwide HEOR – US Market, Immunology, Bristol Myers SquibbObjective This study aimed to compare treatment patterns and healthcare costs for patients with psoriasis who initiate apremilast, tumor necrosis factor inhibitor, or interleukin inhibitor. Methods This retrospective cohort study used Optum Clinformatics® Data Mart to identify propensity score–matched patients initiating apremilast, tumor necrosis factor inhibitors, or interleukin inhibitors, with 12-month baseline and 24-month follow-up data. Switch, discontinuation, persistence, healthcare resource utilization, and total healthcare costs were assessed. Results Twenty-four-month switch rates were highest for tumor necrosis factor inhibitors (32%), followed by apremilast (21%) then interleukin inhibitors (14%). Mean (SD) per-patient-per-month costs for switchers were lowest for apremilast ($4213 [$2304]), higher for tumor necrosis factor inhibitors ($5274 [$2280]), and highest for interleukin inhibitors ($5539 [$2296]; p < .001), primarily attributable to pharmacy costs: $3466 (apremilast), $4432 (tumor necrosis factor inhibitor), and $4721 (interleukin inhibitor). Limitations Psoriasis severity is absent from claims data; cost outcomes may be influenced by more severe psoriasis being more costly. Conclusion Switching psoriasis treatment is common and increases over time. Apremilast initiators had lower switch rates and costs compared with tumor necrosis factor inhibitors, despite lower effectiveness reported in previous studies, perhaps indicating patient preference for oral treatment. Additional oral options may be desirable for this population.http://dx.doi.org/10.1080/09546634.2023.2177095healthcare resource utilizationinterleukin inhibitorpersistencetumor necrosis factor inhibitor |
| spellingShingle | Jashin J. Wu Ching An Wang Greeta Jobson David Davidson Samaneh Kalirai Julia Zhu Manasi Suryavanshi Mayank Mittal Vardhaman Patel Lauren Seigel Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis Journal of Dermatological Treatment healthcare resource utilization interleukin inhibitor persistence tumor necrosis factor inhibitor |
| title | Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis |
| title_full | Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis |
| title_fullStr | Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis |
| title_full_unstemmed | Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis |
| title_short | Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis |
| title_sort | treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics a retrospective claims database cohort analysis |
| topic | healthcare resource utilization interleukin inhibitor persistence tumor necrosis factor inhibitor |
| url | http://dx.doi.org/10.1080/09546634.2023.2177095 |
| work_keys_str_mv | AT jashinjwu treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT chinganwang treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT greetajobson treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT daviddavidson treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT samanehkalirai treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT juliazhu treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT manasisuryavanshi treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT mayankmittal treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT vardhamanpatel treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis AT laurenseigel treatmentpatternsandhealthcarecostsamongpatientswithpsoriasisinitiatingapremilastorbiologicsaretrospectiveclaimsdatabasecohortanalysis |